Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also operates through SecureDose Synthetics Inc., which is a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.


CSE:PHRX - Post by User

Comment by SamRothsteinon Mar 25, 2021 12:20pm
60 Views
Post# 32875736

RE:RE:RE:RE:It takes $200 Million plus for a Phase III approval

RE:RE:RE:RE:It takes $200 Million plus for a Phase III approval

I am really having a hard time believing this guy is ceo of public company.  I don't think someone in that postion would be dumb enough to open themselves up to serous legal issues by repeatedly postinh that a roll back is definitely happening when they have zero proof of that.  I see that is backpedaling a little bit now and saying he only thinks this will happen, but he presented it as absolute fact since November.  Only with several board members attacking his post did he soften it.  

Doinitmyway wrote:
Jeff.....the 70 million you keep tossing around (if that amount is even accurate) would be the final amount needed as you say under orphan drug status. You are talking about several years before phase 3 is complete. Which gives plenty of time to secure funding via many means, ample time for share price to increase as well (helping to secure funding more so), company gets bought out (negating need for funding) and don't forget the companies plans for roll out of cannabis dispensary across the EU under pharmadrug and the shroom business expansion expanding under Slim Winkel in the Netherlands and I believe the EU as well....which will all contribute to bottom line and increasing share value. With all that said I struggle to see your point with the urgency to come up with this quoted 70 million at your fever pitch. Read up before you bash eh....

 

<< Previous
Bullboard Posts
Next >>